Clarus Therapeutics Holdings, Inc. [Rocket]

Overview

Clarus Therapeutics Holdings, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
03/07/2023	EFFECT	Form EFFECT - Notice of Effectiveness:
03/07/2023	EFFECT	Form EFFECT - Notice of Effectiveness:
03/07/2023	EFFECT	Form EFFECT - Notice of Effectiveness:
03/07/2023	EFFECT	Form EFFECT - Notice of Effectiveness:
03/01/2023	15-12G	Form 15-12G - Securities registration termination [Section 12(g)]:
03/01/2023	8-K	Quarterly results
03/01/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19
Revenues	14.0	6.4	0.0
Revenue growth	119.1%
Cost of goods sold	2.7	8.7	0.0
Gross profit	11.2	-2.3	0.0
Gross margin	80.5%	-36.4%
Sales and marketing	30.7	30.5	7.4
Research and development	3.6	2.4	3.1
General and administrative	16.7	11.9	7.4
EBIT	-23.8	34.5	5.9
EBIT margin	-170.8%	541.6%
Pre-tax income	-40.6	4.3	-41.7
Income taxes	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%
Net income	-40.2	-10.3	-41.7
Net margin	-288.1%	-162.3%

Diluted EPS	($5.72)	($1.21)	($20.54)
Shares outstanding (diluted)	7.0	8.5	0.9

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.